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Nicola Mozzillo and Paolo A Ascierto*Stage IV melanoma has historically been associated with
poor outcomes, with a typical one-year survival rate of
around 25% [1]. In particular, patients who develop distant
metastases have a poor prognosis. Treatment of these
patients involves systemic medical therapy, radiotherapy
and surgery.
However, systemic drug therapy as a treatment option
has generally been ineffective in metastatic melanoma.
Although several single-agent chemotherapies have shown
activity against melanoma, complete responses are rare,
with overall response rates of 8–23% and median overall
survival (OS) of 6–11 months [2]. A meta-analysis of 48
studies demonstrated that the benefit from any of the vari-
ous combinations of chemotherapy and biochemotherapy
is about 4.2%, with a mean OS of 6 months [3].
However, recent years have seen an improvement in
our understanding of the melanoma metastatic cascade,
providing important new information about the molecu-
lar events that drive melanoma initiation and progres-
sion and allowing the development of novel therapies. In
2011, ipilimumab was the first new agent approved for
the treatment of patients with advanced melanoma in
over three decades. Ipilimumab is a fully human mono-
clonal antibody directed against cytotoxic T-lymphocyte-
associated antigen-4 (CTLA-4), a negative regulator of
T-cell-mediated immune responses. In phase III trials,
treatment with ipilimumab significantly extended OS
compared with control in both pre-treated and treatment-
naϊve patients, and follow-up data from clinical trials sug-
gest ipilimumab can provide durable clinical benefit and
long-term survival [4,5]. The patterns of tumour response
to ipilimumab differ from those observed with cytotoxic
chemotherapies, since patients may have a delayed yet
durable response and obtain long-term survival benefit
despite initial tumour growth. Approximately 10% of pa-
tients have objective responses by standard criteria, whereas
10–20% show stable disease or minor responses that* Correspondence: paolo.ascierto@gmail.com
Department of Melanoma and Soft Tissue, Istituto Nazionale Tumori
Fondazione “G. Pascale”, Via Mariano Semmola, 80131 Naples, Italy
© 2014 Mozzillo and Ascierto; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.translate into a clinical benefit [6,7]. In most patients, the
onset of clinical response is between weeks 12 and 24 and
may persist for ≥1 year before maximal response occurs.
The first targeted therapy for advanced melanoma
with a favorable impact on survival, vemurafenib, was
also approved in 2011. Vemurafenib is a tyrosine kinase
inhibitor of the oncogenic BRAFV600 protein kinase.
Approximately 50% of melanomas harbour activating
BRAF mutations, especially those patients with tumours
arising on skin without chronic sun-induced damage [8].
In clinical trials, treatment with vemurafenib was asso-
ciated with an OS of 77% at 6 months and 58% at
12 months, although median OS remained at 13.6 months
due to disease relapses [9,10]. Other targeted therapies are
also in development, either with the same molecular
target (e.g. dabrafenib), or targeting steps in the pathway
downstream of BRAF (e.g. MEK inhibitors). Further
improvements in targeted approaches are expected from
ongoing clinical trials, aiming to potentiate the activity of
BRAF inhibitors through combined or sequential therapy
with other molecules, both immune-based and other tar-
geted agents [11]. These combination therapies (e.g. BRAF
plus MEK inhibitors) also aim at lowering the skin toxic-
ities observed with BRAF inhibition.
Despite the major advances offered by these new sys-
temic therapies, surgery of stage IV melanoma remains
an important therapeutic tool that can be used to rapidly
and safely resolve localised disease. The rational for sur-
gical resection as first option in stage IV melanoma is
based on several factors. Single lesions are best treated
by surgery while studies have shown complete resection
is possible in 25% of stage IV patients (M1a through
M1c inclusive) [12]. The surgical procedure has accept-
able morbidity and mortality and is associated with
favourable survival rates [13].
Several prognostic factors for surgery in metastatic
melanoma have been identified (Table 1). In particular,
patients who have limited sites of metastatic disease,
prolonged disease-free survival and a tumour-volume
doubling time of >60 days may be amenable to surgicalCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Prognostic factors for surgical resection in stage
IV melanoma
Major Ability to achieve complete surgical resection
Initial site of metastasis
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the disease burden can be completely resected. Complete
surgical excision of limited metastatic disease can result in
prolonged progression-free survival (PFS) in carefully se-
lected patients. Surgery for distant metastatic melanoma,
however, is rarely curative since the majority of patients
with distant metastases have widespread micrometastatic
disease even if clinical and imaging criteria suggest limited
spread.
The rationale for considering surgery as a major compo-
nent of metastatic melanoma therapy is further supported
by the observation that repeat resection of recurrent dis-
tant metastatic melanoma can prolong survival and that
metastases can themselves metastasize. The potential for
surgery to benefit individual patients is suggested by the
results of a prospective, phase II study from the Southwest
Oncology Group, in which 64 of 77 carefully selected
patients underwent complete resection of all sites of meta-
static disease [17]. At a median follow-up of five years, the
median durations of PFS and OS were 5 and 21 months,
respectively. Overall, the three- and four-year survival
rates were 36% and 31%, although late relapses continued
to be observed after this time. Resection should be re-
served for the relief or prevention of morbidity due to
local tumor growth and for patients in whom a longer sur-
vival might be expected with surgical rather than medical
treatment.
Large tumour masses are difficult to eradicate with sys-
temic therapy alone and surgery in combination with novel
immuno- and targeted therapies can potentially improve
clinical outcomes and/or patients’ quality of life. Indeed,
surgery should be offered to reduce the target of subse-
quent adjuvant medical treatment whenever possible.
BRAF inhibitors (vemurafenib and dabrafenib) alone
and in combination (dabrafenib/trametinib, vemurafenib/
cobimetinib, encorafenib/binimetinib) can have a signifi-
cant clinical impact with a rapid improvement in symp-
toms and metabolic shut-down at PET scan assessment.
However, not all metastatic sites respond to therapy and
surgery may be required to remove resistant lesions. Data
from a phase I study [18] and from an expanded access
program [19] clearly indicate improved PFS and OS in
patients with a low tumoural volume, suggesting that the
use of surgery to remove resistant clones and reducetumour burden may be beneficial. Indeed, data from
a phase I trial evidenced that, for a subset of patients
with disease progression, continuation of vemurafenib
treatment is potentially beneficial after local therapy
[20]. In this study, 18 patients who continued vemur-
afenib >30 days after surgery or radiotherapy at a site
of disease progression had a median overall survival
of over 15.5 months from initiation of BRAF inhibitor
therapy. This compares with a median overall survival
of 1.4 months in patients who did not continue treatment.
Moreover, patients with low tumour burden seemed to
have a better response to vemurafenib.
Surgery may also have an important role in combination
with immunotherapy. Indeed, the removal of lesions that
may be resistant to treatment with ipilimumab may im-
prove outcomes for some patients. Pathological evaluation
of the excised tissue is important to assess the presence of
immune-infiltrate. In several cases, analysis of the excised
tissue has revealed the presence of a diffuse immune infil-
tration which correlated with the outcome of these pa-
tients [21]. Thus, reduction of the tumor mass which can
be obtained with surgery is important in combination with
immunotherapy.
In conclusion, surgery still represents one of the four
pillars of treatment for stage IV melanoma, together with
radiotherapy, chemotherapy and new immunotherapy
approaches.
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